<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amitriptyline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amitriptyline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amitriptyline: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8605" href="/d/html/8605.html" rel="external">see "Amitriptyline: Drug information"</a> and <a class="drug drug_patient" data-topicid="10829" href="/d/html/10829.html" rel="external">see "Amitriptyline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708615"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of amitriptyline in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Amitriptyline is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865894"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Amitriptyline;</li>
<li>Amitriptyline-10;</li>
<li>Amitriptyline-25;</li>
<li>APO-Amitriptyline;</li>
<li>Elavil;</li>
<li>JAMP-Amitriptyline;</li>
<li>Mar-Amitriptyline;</li>
<li>PMS-Amitriptyline;</li>
<li>PRIVA-Amitriptyline [DSC];</li>
<li>TEVA-Amitriptyline</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050991"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidepressant, Tricyclic (Tertiary Amine)</span>;</li>
<li>
<span class="list-set-name">Antimigraine Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F133763"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b64fb919-4306-4557-a5ec-d4c88dd60d93">Chronic pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic pain management:</b> Limited data available: Children and Adolescents: Oral: Initial: 0.1 mg/kg at bedtime; may advance as tolerated over 2 to 3 weeks to 0.5 to 2 mg/kg at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-17933616','lexi-content-ref-Zeltzer.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-17933616','lexi-content-ref-Zeltzer.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7fc4235-c695-4f6f-8b85-6a2ed65e8502">Cyclic vomiting syndrome, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, prophylaxis: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prophylaxis is recommended for patients experiencing frequent symptoms (eg, monthly) or severe symptoms (eg, requiring hospitalization, lasting &gt;2 days, resulting in significant school/work absences) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral: Initial: 0.2 to 0.5 mg/kg/day once daily, administered at bedtime. If needed, may titrate every 1 to 2 weeks (eg, by 5 to 10 mg increments) to a usual dose of 1 to 1.5 mg/kg/day; doses of 2 mg/kg/day or higher have been described; however, should be used with caution with careful titration, ECG monitoring, and therapeutic monitoring; doses may be divided for tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9374568','lexi-content-ref-30076469','lexi-content-ref-18728540','lexi-content-ref-33224097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9374568','lexi-content-ref-30076469','lexi-content-ref-18728540','lexi-content-ref-33224097'])">Ref</a></span>). In adults, the mean effective dose is 75 to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents. Although dosing is included in some manufacturer's labeling for ages ≥12 years, a selective serotonin reuptake inhibitor (SSRI) is recommended first line for treatment of depression in children and adolescents with/without psychotherapeutic interventions. Amitriptyline may be beneficial for patients in whom first- and/or second-line treatment options have failed or with comorbid conditions (eg, migraines, chronic pain) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18049300','lexi-content-ref-31413171','lexi-content-ref-29483201','lexi-content-ref-30397569','lexi-content-ref-NICE.3','lexi-content-ref-33276542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18049300','lexi-content-ref-31413171','lexi-content-ref-29483201','lexi-content-ref-30397569','lexi-content-ref-NICE.3','lexi-content-ref-33276542'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Usual initial range: 20 to 30 mg/day at bedtime or in divided doses (eg, 10 mg 3 times daily); titrate slowly at weekly intervals; maximum daily dose: 200 mg/<b>day</b>; in general, lower doses are recommended compared to doses in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9585655','lexi-content-ref-Gal.2007','lexi-content-ref-7031113','lexi-content-ref-Nelson.1996','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9585655','lexi-content-ref-Gal.2007','lexi-content-ref-7031113','lexi-content-ref-Nelson.1996','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a88a9dbf-8161-4267-8b85-a53eda1346a9">Migraine, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prophylaxis:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10940092','lexi-content-ref-23594025','lexi-content-ref-15623677','lexi-content-ref-27788026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10940092','lexi-content-ref-23594025','lexi-content-ref-15623677','lexi-content-ref-27788026'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pediatric migraine efficacy trials have been observed to have a high placebo response; a meta-analysis has shown that 30% to 61% of subjects receiving placebo report decreased number of migraine attacks or decrease in headache days. Specific to amitriptyline therapy, there is insufficient evidence in pediatric subjects to demonstrate a 50% reduction in headache frequency, headache days, and migraine-related disability compared to placebo. When amitriptyline is combined with cognitive behavioral therapy (CBT), trials have shown a reduction in number of headache days and migraine-related disability compared with amitriptyline plus headache education (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413171','lexi-content-ref-23594025','lexi-content-ref-24368463','lexi-content-ref-27788026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413171','lexi-content-ref-23594025','lexi-content-ref-24368463','lexi-content-ref-27788026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents: Oral: Initial: 0.25 mg/kg/day once daily at bedtime; increase dose by 0.25 mg/kg/day every 2 weeks to 1 mg/kg/day; maximum daily dose: 100 mg/<b>day</b>; combining amitriptyline with CBT may also be effective at reducing headache days and migraine-related disability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23594025','lexi-content-ref-24368463']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23594025','lexi-content-ref-24368463'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Depression: Consider planning antidepressant discontinuation for lower-stress times, recognizing non–illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively, avoiding abrupt discontinuation of the medication to prevent withdrawal effects. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164','lexi-content-ref-12479080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164','lexi-content-ref-12479080'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the antidepressant before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks but may increase the risk for the development of adverse effects or serotonin syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects such as increased suicidal thoughts and behaviors or worsening depression or mania. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064775"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; however, renally eliminated; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51064776"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; however, hepatically metabolized; use with caution.</p></div>
<div class="block doa drugH1Div" id="F133743"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8605" href="/d/html/8605.html" rel="external">see "Amitriptyline: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc4648c3-d32a-449b-a45c-1ebfc2a6f8f8">Chronic fatigue syndrome related sleep disorders and pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic fatigue syndrome related sleep disorders and pain (off-label use): </b>Based on limited evidence; recommendations based on expert opinion: <b>Oral:</b> Initial: 10 mg once daily 1 hour before bedtime; may increase dose gradually based on response and tolerability in 10 mg increments up to 50 mg/day at bedtime for sleep disorders; for patients with pain, titrate up to 100 mg/day given once daily at bedtime or in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Carruthers.2003','lexi-content-ref-Gluckman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Carruthers.2003','lexi-content-ref-Gluckman.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fc78923-c3d1-4aa8-9d26-05bc0308cd04">Cyclic vomiting syndrome, moderate to severe, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, moderate to severe, prevention </b>
<b>(off-label use):</b>
<b>Oral: </b>Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in increments of 10 to 25 mg at weekly intervals up to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36791365','lexi-content-ref-20027010','lexi-content-ref-31241819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36791365','lexi-content-ref-20027010','lexi-content-ref-31241819'])">Ref</a></span>). Typically requires a trial of 1 to 2 months at a therapeutic dose to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Li.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Li.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ad982f6-abe6-4e23-89e9-30b803d922e2">Fibromyalgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily, 1 to 3 hours before bedtime; gradually increase dose based on response and tolerability in 5 to 10 mg increments at intervals of ≥2 weeks up to 75 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8129762','lexi-content-ref-27377815','lexi-content-ref-Goldenberg.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8129762','lexi-content-ref-27377815','lexi-content-ref-Goldenberg.2020'])">Ref</a></span>). <b>Note:</b> Some experts suggest lower starting doses of 5 mg once daily in patients sensitive to side effects and that a maintenance dose range of 20 to 30 mg/day is often adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98364f85-c921-4565-8d52-e57d073319cb">Functional dyspepsia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Functional dyspepsia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used to augment or replace proton pump inhibitor therapy in partial and nonresponders who have been tested for <i>H. pylori </i>and treated if positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in increments of 10 to 25 mg at ≥1-week intervals up to a maximum of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21767283','lexi-content-ref-Longstreth.2018','lexi-content-ref-25921377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21767283','lexi-content-ref-Longstreth.2018','lexi-content-ref-25921377'])">Ref</a></span>). Some experts suggest a lower maintenance dose range of 20 to 30 mg/day. Typically requires a trial of 8 to 12 weeks at a therapeutic dose to adequately assess efficacy. If effective, reassess at 6 months and consider tapering; may resume if dyspepsia recurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b274fd4e-19be-4b90-b849-47c46fdbf3a4">Headache, chronic tension-type</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Headache, chronic tension-type (prevention) (off-label use):</b>
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in 10 to 25 mg increments at intervals of ≥1 week up to 125 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8795600','lexi-content-ref-20482606','lexi-content-ref-Taylor.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8795600','lexi-content-ref-20482606','lexi-content-ref-Taylor.2018'])">Ref</a></span>). A lower starting dose of 10 to 12.5 mg once daily at bedtime and smaller titration increments of 10 to 12.5 mg/day at 2- to 3-week intervals may reduce adverse effects and enhance adherence according to some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Taylor.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Taylor.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b>
<b>Oral:</b> Initial: 10 mg once daily at bedtime; based on response and tolerability, increase dose after 1 week to 25 mg once daily and then at weekly intervals in 25 mg increments to a target dose of 75 to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hanno.2014','lexi-content-ref-20303115','lexi-content-ref-15247722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hanno.2014','lexi-content-ref-20303115','lexi-content-ref-15247722'])">Ref</a></span>). A maximum dose of up to 75 mg/day as tolerated is suggested by some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clemens.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clemens.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec3569cc-faed-492b-a46e-162b8fa6d4d2">Irritable bowel syndrome-associated pain and global symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome-associated pain and global symptoms (alternative agent) (off-label use):</b>
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may gradually increase dose based on response and tolerability to a recommended dose of 50 to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591','lexi-content-ref-9715427','lexi-content-ref-18248658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591','lexi-content-ref-9715427','lexi-content-ref-18248658'])">Ref</a></span>). Some experts recommend 3 to 4 weeks of therapy before increasing the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (alternative agent):</b>
<b>Oral:</b> Initial: 25 to 50 mg/day as a single dose at bedtime or in divided doses; increase dose based on response and tolerability in 25 to 50 mg increments at intervals of ≥1 week up to a usual dose of 100 to 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018','lexi-content-ref-VADod.2016','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018','lexi-content-ref-VADod.2016','lexi-content-ref-23879318'])">Ref</a></span>). Some experts suggest an initial dose of 25 mg/day at bedtime for most patients, although higher starting doses of 50 to 100 mg/day and more rapid titration (eg, every few days) may be considered in closely supervised (eg, hospitalized) settings; for patients sensitive to adverse effects, may initiate with 10 mg daily with gradual titration in steps of 10 mg/day every few days or longer (eg, at intervals ≥1 week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling</i>: Dosing in prescribing information may not reflect current clinical practice. Oral: Initial: 75 to 100 mg/day as a single dose at bedtime or in divided doses</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; increase dose based on response and tolerability in 10 to 25 mg increments at intervals of ≥1 week up to 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22683887','lexi-content-ref-19393844','lexi-content-ref-19708964','lexi-content-ref-18620801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22683887','lexi-content-ref-19393844','lexi-content-ref-19708964','lexi-content-ref-18620801'])">Ref</a></span>). Some experts suggest that a lower maintenance dose range of 10 to 100 mg once daily at bedtime is often adequate and better tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33da3206-1780-49f6-8ed0-58b616ea7ab4">Myofascial pain syndrome and related causes of chronic pain including myofascial pelvic pain, nonradicular neck pain, temporomandibular disorders, and vulvodynia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myofascial pain syndrome and related causes of chronic pain including myofascial pelvic pain, nonradicular neck pain, temporomandibular disorders, and vulvodynia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider for patients with persistent symptoms despite multimodal care and treatment with first-line agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9586488','lexi-content-ref-16416358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9586488','lexi-content-ref-16416358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may increase based on response and tolerability in 10 to 25 mg increments at intervals ≥1 week to a usual dosage range of 25 to 75 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25905532','lexi-content-ref-30129937','lexi-content-ref-10099756','lexi-content-ref-11065017','lexi-content-ref-12889679','lexi-content-ref-16416358','lexi-content-ref-29202395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25905532','lexi-content-ref-30129937','lexi-content-ref-10099756','lexi-content-ref-11065017','lexi-content-ref-12889679','lexi-content-ref-16416358','lexi-content-ref-29202395'])">Ref</a></span>). Maximum: 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9586488','lexi-content-ref-16416358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9586488','lexi-content-ref-16416358'])">Ref</a></span>); due to tolerability concerns, some experts avoid or use caution with nortriptyline doses &gt;50 mg/day (nortriptyline and amitriptyline are equipotent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25911132','lexi-content-ref-Isaac.1','lexi-content-ref-Mehta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25911132','lexi-content-ref-Isaac.1','lexi-content-ref-Mehta.1'])">Ref</a></span>). May require 6 to 12 weeks of therapy (including 2 weeks at maximum tolerated dose) to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mehta.1','lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mehta.1','lexi-content-ref-Tauben.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b3bff7b-0a4e-4eab-9f29-126e5efad7bc">Neuropathic pain, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain, chronic (including diabetic neuropathy) (alternative agent) (off-label use):</b>
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may gradually increase dose based on response and tolerability in 10 to 25 mg increments at intervals ≥1 week up to a usual dosage range of 25 to 125 mg/day once daily at bedtime or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27999003','lexi-content-ref-8736630','lexi-content-ref-Garza.1','lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27999003','lexi-content-ref-8736630','lexi-content-ref-Garza.1','lexi-content-ref-Tauben.1'])">Ref</a></span>). Maximum: 150 mg/day given once daily at bedtime or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8736630','lexi-content-ref-17372630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8736630','lexi-content-ref-17372630'])">Ref</a></span>). In patients with diabetic neuropathy, some experts recommend a maximum dose of 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.1'])">Ref</a></span>). May require 6 to 12 weeks of therapy (including 2 weeks at maximum tolerated dose) to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tauben.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd263141-59d9-4f4b-8e26-25d16a66c401">Postherpetic neuralgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia (off-label use):</b>
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may gradually increase dose based on response and tolerability in 10 to 25 mg increments at intervals of ≥1 week up to 150 mg/day given once daily at bedtime or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11014390','lexi-content-ref-3412591','lexi-content-ref-16275598','lexi-content-ref-6283422','lexi-content-ref-1738571','lexi-content-ref-9781549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11014390','lexi-content-ref-3412591','lexi-content-ref-16275598','lexi-content-ref-6283422','lexi-content-ref-1738571','lexi-content-ref-9781549'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4c15035-f4ec-4814-9029-cd0375c0f277">Sialorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sialorrhea (off-label use):</b>
<b>Oral:</b> Usual dose: 10 to 25 mg once daily at bedtime. If necessary, may gradually increase dose based on response and tolerability up to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21914052','lexi-content-ref-16939528','lexi-content-ref-27113954','lexi-content-ref-22487791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21914052','lexi-content-ref-16939528','lexi-content-ref-27113954','lexi-content-ref-22487791'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include use of a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine), prior history of antidepressant withdrawal symptoms, or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23879318','lexi-content-ref-Hirsch.2019c','lexi-content-ref-23459282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23879318','lexi-content-ref-Hirsch.2019c','lexi-content-ref-23459282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of amitriptyline.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing amitriptyline and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991382"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6723762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6723762'])">Ref</a></span>); however, dialysis patients have demonstrated increased sensitivity to the anticholinergic side effects of tricyclic antidepressants (TCAs) (potentially due to accumulation of glucuronide metabolites). Use with caution (or avoid use) along with close monitoring for both anticholinergic and QT prolonging effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4049459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4049459'])">Ref</a></span>); however, dialysis patients have demonstrated increased sensitivity to the anticholinergic side effects of TCAs (potentially due to accumulation of glucuronide metabolites). Use with caution (or avoid use) along with close monitoring for both anticholinergic and QT prolonging effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Unlikely to be dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988564"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, hepatically metabolized; use with caution. Some experts recommended reducing initial and maintenance doses by 50% in patients with hepatic impairment, with cautious dose adjustments based on response and tolerability; maximum 100 mg/day (Mauri 2014; Mullish 2014).</p></div>
<div class="block arsc drugH1Div" id="F54497904"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline may cause anticholinergic effects, such as <b>constipation </b>(including fecal impaction), <b>xerostomia</b>, <b>blurred vision</b>, and <b>urinary retention</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Binding affinity to the muscarinic receptor(s), permeability of the blood-brain barrier, and serum and tissue concentrations all influence the risk of anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25735839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25735839'])">Ref</a></span>). Amitriptyline is considered to have high anticholinergic activity at typical doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-11250852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-11250852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riedel.1995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riedel.1995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riedel.1995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riedel.1995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs with anticholinergic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Riedel.1995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Riedel.1995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific tricyclic antidepressants: Amitriptyline has the highest degree of anticholinergic effects, while desipramine and nortriptyline have modest effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009','lexi-content-ref-Riedel.1995','lexi-content-ref-11250852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009','lexi-content-ref-Riedel.1995','lexi-content-ref-11250852'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/anticoagulants. Multiple observational studies with other drugs that interfere with serotonin reuptake (eg, selective serotonin reuptake inhibitors [SSRIs]) have found an association with use and a variety of bleeding complications. Similar to these agents, amitriptyline may increase the risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via inhibition of serotonin-mediated platelet activation and subsequent platelet dysfunction. Amitriptyline is considered to display intermediate affinity for the serotonin reuptake receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-18188866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-18188866'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; per SSRI-derived literature (ie, amitriptyline not included), bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of antiplatelet agents and/or anticoagulants (based on SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiac conduction abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline may cause dose-dependent <b>ECG changes </b>(nonspecific), most commonly QRS prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4022081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4022081'])">Ref</a></span>), <b>atrioventricular conduction disturbance</b>, and <b>cardiac arrhythmias</b>, including <b>sinus</b>
<b>tachycardia</b>. QT prolongation and ventricular arrhythmias may also occur. May precipitate heart block in patients with preexisting conduction system disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Inhibits cardiovascular sodium, calcium, and potassium channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15320756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15320756'])">Ref</a></span>). Sinus tachycardia is attributed to the inhibition of norepinephrine and anticholinergic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roos.1983','lexi-content-ref-28709467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roos.1983','lexi-content-ref-28709467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of metabolic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration of drugs independently associated with QT interval prolongation or further increase risk of arrhythmia (amitriptyline shares electrophysiologic properties of type Ia antiarrhythmics such as quinidine, procainamide, and disopyramide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8444830','lexi-content-ref-15320756','lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8444830','lexi-content-ref-15320756','lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>). <b>Note:</b> Use is relatively contraindicated in patients with conduction abnormalities</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline may cause dose-dependent CNS depression, including <b>dizziness</b>, <b>drowsiness</b>, a <b>sedated state,</b>
<b>ataxia</b>, <b>cognitive dysfunction</b>, <b>confusion</b>,<b> disorientation</b>, and <b>fatigue</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose related; alpha-adrenergic and histamine receptor blockade may cause dizziness (via orthostatic hypotension) and a high degree of sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009','lexi-content-ref-10383563','lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009','lexi-content-ref-10383563','lexi-content-ref-2140373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; difficult to define; some symptoms may occur with first dose. A meta-analysis in inpatients treated with a tricyclic antidepressant (TCA), including amitriptyline, suggested that CNS toxicity (defined primarily as delirium or its prodromal symptoms) may have an insidious onset over 1 to 3 weeks following initiation or dose increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant CNS depressants (eg, anticholinergics, antihistamines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased age (&gt;55 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased TCA plasma levels, especially levels &gt;300 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific TCA: Amitriptyline has the highest risk of sedation among the TCAs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (primarily selective serotonin reuptake inhibitors [SSRIs]) have been associated with an increased risk of bone fractures in observational studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17242321','lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17242321','lexi-content-ref-22659406'])">Ref</a></span>). Tricyclic antidepressants, including amitriptyline, have also been associated with increased fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not fully elucidated; per SSRI-derived literature, may be related to a direct effect on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). Fall risk may be attributed to sedation, syncope, orthostatic hypotension, and/or confusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in a large, population-based case-controlled study, the increase risk of fracture with amitriptyline was more pronounced within the first 6 months of initiating therapy and declined with increasing duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; amitriptyline is associated with fractures at low doses and a dose-dependent increase in risk has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18219438'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with other agents that may further affect physical balance and contribute to falls (eg, anxiolytics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24566587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24566587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs) have been rarely associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or hyponatremia, predominately in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; overall, hyponatremia risk is much higher within 2 to 4 weeks of initiating therapy and the risk seems to diminish over time. By 3 to 6 months, the hyponatremia risk is the same as for patients who do not take antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Volume depletion (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Specific antidepressant: TCAs have a lower risk for hyponatremia in comparison to selective serotonin reuptake inhibitors (SSRIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline is associated with acute angle-closure glaucoma (AACG) in a case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5923732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5923732'])">Ref</a></span>). May cause mild pupillary dilation, which, in susceptible individuals, can result in physical obstruction of the outflow of intraocular fluid. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May occur due to anticholinergic activity and mydriasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20443647'])">Ref</a></span>). May also be related to effects on serotonin or norepinephrine receptors in the iris and ciliary body of the eye (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i> • </i>Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i> • </i>≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i> • </i>Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i> • </i>Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i> • </i>Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline may cause <b>orthostatic hypotension</b>, which may lead to<b> syncope</b> and subsequent falls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-9826316','lexi-content-ref-11126303','lexi-content-ref-1592445','lexi-content-ref-23265229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-9826316','lexi-content-ref-11126303','lexi-content-ref-1592445','lexi-content-ref-23265229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Alpha-adrenergic receptor blockade may lower systemic vascular resistance and result in hypotension, including orthostatic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; unclear; in a small study of elderly patients treated with amitriptyline 100 mg, orthostatic hypotension remained throughout the entire 5-week study period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3931149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3931149'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Hypovolemia/dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent medication use that may predispose to hypotension/bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older adults, especially in those with preexisting heart conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-29937420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-29937420'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Specific TCA: Amitriptyline is usually associated with a high risk for significant orthostatic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8444830','lexi-content-ref-32894454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8444830','lexi-content-ref-32894454'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8968471','lexi-content-ref-12243617','lexi-content-ref-9031998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8968471','lexi-content-ref-12243617','lexi-content-ref-9031998'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of suicidal thinking and suicidal behavior in pediatric and young adult patients (18 to 24 years) in short-term studies. In adults &gt;24 years, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304','lexi-content-ref-8452661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304','lexi-content-ref-8452661'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability) has been reported, primarily following abrupt discontinuation of selective serotonin reuptake inhibitors (SSRIs). Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8471189','lexi-content-ref-6324897','lexi-content-ref-16683858','lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8471189','lexi-content-ref-6324897','lexi-content-ref-16683858','lexi-content-ref-15014601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the serotonergic agent. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>). May also be related in part to an adaptive hypersensitivity of muscarinic cholinergic receptors called cholinergic rebound or cholinergic overdrive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; based on data of withdrawal syndrome following SSRI discontinuation, expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16683858','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16683858','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Abrupt discontinuation (rather than gradual dose reduction) of an antidepressant treatment that has lasted for &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a','lexi-content-ref-15906018','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a','lexi-content-ref-15906018','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019a'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019a'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F133703"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Anticholinergic effects may be pronounced; moderate to marked sedation can occur (tolerance to these effects usually occurs).</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrioventricular conduction disturbance, cardiac arrhythmia, cardiomyopathy (rare) (Briec 2006), cerebrovascular accident, ECG changes (nonspecific) (Boehnerr 1985), edema, exacerbation of cardiac disease (AHA [Page 2016]), facial edema, heart block, hypertension, orthostatic hypotension, palpitations, sinus tachycardia, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin rash, alopecia, diaphoresis, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered serum glucose (inconclusive, but increased weight gain may increase insulin resistance) (Gagnon 2018), decreased libido, galactorrhea not associated with childbirth, gynecomastia, increased libido, SIADH, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, anorexia, constipation, melanoglossia, nausea, paralytic ileus, parotid gland enlargement, stomatitis, unpleasant taste, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy, impotence, testicular swelling, urinary frequency, urinary retention, urinary tract dilation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis (rare; including altered liver function and jaundice)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, ataxia, cognitive dysfunction, coma, confusion, delusion, disorientation, dizziness, drowsiness, dysarthria, EEG pattern changes, excitement, extrapyramidal reaction (including abnormal involuntary movements and tardive dyskinesia), fatigue, hallucination, headache, hyperpyrexia, insomnia, lack of concentration, nightmares, numbness, paresthesia, peripheral neuropathy, restlessness, sedated state, seizure, suicidal ideation, suicidal tendencies, tingling of extremities</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, lupus-like syndrome, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blurred vision, increased intraocular pressure, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Azadeh 2014), thrombocytopenia (Taniguchi 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuroleptic malignant syndrome (rare) (Corrigan 1988; Janati 2012; Stevens 2008), serotonin syndrome (rare) (Dougherty 2002; Perry 2000), withdrawal syndrome (rare: &lt;1%) (Davison 1993; Dilsaver 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma (rare: &lt;1%) (Lowe 1966)</p></div>
<div class="block coi drugH1Div" id="F133721"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amitriptyline or any component of the formulation; coadministration with or within 14 days of MAOIs; coadministration with cisapride; acute recovery phase following myocardial infarction</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Severe liver impairment; acute heart failure</p></div>
<div class="block war drugH1Div" id="F133700"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility (eg, paralytic ileus) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased, and plasma concentrations are increased. Due to the narrow therapeutic index, use lower initial and maintenance doses of tricyclic antidepressants. Use caution in patients with hepatic encephalopathy due to the risk of neurocognitive effects (Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Combination therapy with an antidepressant and a mood stabilizer should also be avoided in acute mania or mixed episodes, as well as maintenance treatment in bipolar disorder due to the mood-destabilizing effects of antidepressants (CANMAT [Yatham 2018]; WFSBP [Grunze 2018]). Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Amitriptyline is not FDA approved for the treatment of bipolar depression.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, increased intraocular pressure, narrow angle glaucoma, visual problems) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Recommended by the manufacturer to discontinue prior to elective surgery; risks exist for drug interactions with anesthesia and for cardiac arrhythmias. However, definitive drug interactions have not been widely reported in the literature and continuation of tricyclic antidepressants is generally recommended as long as precautions are taken to reduce the significance of any adverse events that may occur. Norepinephrine should be considered the vasopressor of choice for TCA-related hypotension (Pass 2004). Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.</p></div>
<div class="block foc drugH1Div" id="F133713"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg</p></div>
<div class="block geq drugH1Div" id="F133696"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F133723"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Amitriptyline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.18 - $0.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.36 - $0.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.71 - $1.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $1.07 - $1.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.43 - $2.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $2.14 - $3.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865895"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elavil: 10 mg, 25 mg, 50 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F52612222"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with food to decrease GI upset.</p></div>
<div class="block adm drugH1Div" id="F23890541"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer higher doses preferably at late afternoon or as bedtime doses to minimize daytime sedation.</p></div>
<div class="block sts drugH1Div" id="F23890526"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p></div>
<div class="block meg drugH1Div" id="F7874280"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at the following website, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Antidepressant medications: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2Fdrugs%2Fdrugsafety%2Fucm088660.pdf&amp;token=8RYIFfyLhIBYEqeX7m6uPPQEVrZ0DF7DWCCLO7W6cf9%2F%2BQ1J8etDBVp%2BC7h2tFOvlFDpOnb8grs5FgzfpCyYCQ%3D%3D&amp;TOPIC_ID=12598" target="_blank">https://www.fda.gov/downloads/drugs/drugsafety/ucm088660.pdf</a></p></div>
<div class="block usep drugH1Div" id="F53565354"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of depression (FDA approved in adults); has also been used as adjunct therapy for chronic pain management, migraine prophylaxis, and prophylaxis of cyclic vomiting syndrome episodes. <b>Note:</b> Although manufacturer's labeling describes dosing in adolescents for depression, use has been replaced by other therapeutic classes with improved efficacy and adverse effect profiles (APA 2019; Cheung 2018; NICE 2019).</p></div>
<div class="block mst drugH1Div" id="F133796"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amitriptyline may be confused with aminophylline, imipramine, nortriptyline</p>
<p style="text-indent:-2em;margin-left:4em;">Elavil may be confused with Aldoril, Eldepryl, enalapril, Equanil, Plavix</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;">Elavil may be confused with Elavil OTC (an over-the-counter sleep aid containing melatonin, valerian root, and vitamins).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Amitriptyline (alone or in combination) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. In addition, use TCAs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F133781"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F133705"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists.  Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Tricyclic Antidepressants may enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.  Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists (Ophthalmic): Tricyclic Antidepressants may diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Tricyclic Antidepressants may enhance the adverse/toxic effect of Amphetamines. Tricyclic Antidepressants may potentiate the cardiovascular effects of Amphetamines. Amphetamines may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased cardiovascular effects when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May increase the metabolism of Tricyclic Antidepressants. Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of BuPROPion. BuPROPion may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Tricyclic Antidepressants may enhance the tachycardic effect of Cannabinoid-Containing Products. Blood pressure raising effects and drowsiness may also be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Tricyclic Antidepressants may enhance the serotonergic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA and citalopram concentrations/effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Tricyclic Antidepressants may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Tricyclic Antidepressants may enhance the arrhythmogenic effect of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations and effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Tricyclic Antidepressants may enhance the serotonergic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: Amitriptyline may enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May enhance the serotonergic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Tricyclic Antidepressants may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Tricyclic Antidepressants may enhance the hypotensive effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: Tricyclic Antidepressants may diminish the therapeutic effect of Lofexidine.  Management: Consider avoiding this drug combination when possible. If concurrent administration is required, monitor blood pressure carefully at the beginning of the combined therapy and when either drug is stopped. Adjust the dosage accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Lorcaserin (Withdrawn From US Market) may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations and effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Tricyclic Antidepressants may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Tricyclic Antidepressants may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Tricyclic Antidepressants may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Tricyclic Antidepressants may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Amitriptyline. Specifically, concentrations of nortriptyline may be reduced. RifAMPin may decrease the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease serum concentrations of the active metabolite(s) of Amitriptyline. Specifically, concentrations of nortriptyline may be reduced. Rifapentine may decrease the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Tricyclic Antidepressants may enhance the CNS depressant effect of Serotonergic Non-Opioid CNS Depressants. Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): Tricyclic Antidepressants may enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May enhance the serotonergic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Amitriptyline. This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Amitriptyline. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and reduced amitriptyline concentrations when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: May enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the anticholinergic effect of other Tricyclic Antidepressants. Tricyclic Antidepressants may enhance the CNS depressant effect of other Tricyclic Antidepressants. Tricyclic Antidepressants may enhance the serotonergic effect of other Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor closely for increased TCA adverse effects, including serotonin syndrome/serotonin toxicity, CNS depression, and anticholinergic effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: Tricyclic Antidepressants may enhance the serotonergic effect of Vilazodone. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Amitriptyline may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: Tricyclic Antidepressants may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57637221"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Tricyclic antidepressants (TCAs) are not preferred for the treatment of depression. However, if a TCA is needed in a patient planning to become pregnant, use of amitriptyline may be considered (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Amitriptyline may be effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p></div>
<div class="block pri drugH1Div" id="F133724"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amitriptyline crosses the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">CNS effects, limb deformities, and developmental delay have been noted in case reports (causal relationship not established). Tricyclic antidepressants (TCAs) may be associated with irritability, jitteriness, and convulsions (rare) in the neonate (Yonkers 2009). Increased crying, constipation, problems with urinating, respiratory distress, and nausea may also occur in neonates exposed during pregnancy (ACOG 2022; Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006). In general, TCAs are not preferred for the treatment of depression and agents other than amitriptyline are preferred if treatment is initiated for the first time during pregnancy (CANMAT [MacQueen 2016]; Larsen 2015). If pregnancy occurs during amitriptyline therapy, close plasma monitoring is recommended to avoid toxicity (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). Efficacy data of amitriptyline for migraine prevention in pregnancy are limited and use is not recommended (ACOG 2022). Amitriptyline may be used if other agents are ineffective or contraindicated, considering the risks and benefits of use (ACOG 2022; CHS [Pringsheim 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Patients 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>
<div class="block mopp drugH1Div" id="F53565338"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, mental status, weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).</p></div>
<div class="block rerp drugH1Div" id="F53565306"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Plasma levels do not always correlate with clinical effectiveness.</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018), with once-daily bedtime dosing draw level 12 to 16 hours after dose (Ziegler 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic reference range: Amitriptyline plus nortriptyline 80 to 200 ng/mL (SI: 288 to 720 nmol/L).</p></div>
<div class="block pha drugH1Div" id="F133699"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane pump.</p></div>
<div class="block phk drugH1Div" id="F133720"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Depression: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~18 to 22 L/kg (Schulz 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid; hepatic N to demethylation to nortriptyline (active), hydroxy derivatives and conjugated derivatives.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~43% to 46% (Schulz 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~13 to 36 hours (Schulz 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~2 to 5 hours (Schulz 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (glucuronide or sulfate conjugate metabolites; little as unchanged drug); Feces (small amounts).</p>
<p style="text-indent:-2em;margin-left:2em;">Special Populations: Older adults: May have increased plasma levels (Schulz 1985).</p></div>
<div class="block phksp drugH1Div" id="F51220431"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: May have increased plasma levels and prolonged half-life (Schulz 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: In women over 50 years of age, plasma amitriptyline concentrations were higher than males in the same age group (Preskorn 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma levels and AUC approximately tripled in a patient with portocaval anastomosis and liver cirrhosis (Hrdina 1985).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F133726"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Apo amitriptyline | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amiptril | Amitriptilina Luar | Fiorda | Tryptalgin | Tryptanol | Uxen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amichlor | Amidep | Amitriptyline | Amitriptyline ac | Amitriptyline an | Amitriptyline arx | Amitriptyline ch | Amitriptyline gppl | Amitriptyline lupin | Amitriptyline pn | Amitriptyline rs | Amitriptyline str | Amitriptyline viatris | Apo amitriptyline | APX AMITRIPTYLINE | Endep | Entrip | Ipca amitriptyline | Pip amitriptyline | Ppa amitriptyline | Tryptanol | Tryptine | Tw amitriptyline</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amilin | Amit | Amitriptyline | Amitryl | Saroten | Serolin | Tryptanol | Tryptin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Redomex | Tryptizol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Arolin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina | Amytril | Cloridrato de amitriptilina | Neo amitriptilin | Protanol | Tripsol | Trisomatol | Tryptanol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Laroxyl | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Arolin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina | Amitriptilina winthrop | Psiquium | Tryptanol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amineurin | Amioxid-neuraxpharm | Amitriptylin | Amitriptylin beta | Amitriptylin CT | Amitriptylin desitin | Amitriptylin fairmed healtcare | Amitriptylin-teva | Equilibrin | Novoprotect | Saroten | Syneudon</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Saroten retard</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina | Sicobil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina | Anapsique | Tryptanol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyliin ns | Amitriptylin | Amitriptylin desitin | Amyzol | Eliwel | Saroten | Tryptisol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amitriptine | Tryptizol | Tryptizole | Tryptoline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Deprelio | Tryptizol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Amileb | Amirol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin abcur | Saroten | Triptyl | Tryptizol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Elavil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline cox | Elavil | Lentizol | Tryptizol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Saroten | Stelminal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amitide | Amitriptyline | Apo amitriptyline | Endep | Saroten | Trepiline | Tryptanol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Amyzol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Teperin | Teperinep</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Amicen | Amitriptyline | Amitriptylline | Trilin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Astilin | Domical | Lentizol | Tryptizol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aldep | Amicon | Amifree | Amilite | Amiscape | Amit | Amitar | Amitone | Amitop | Amitor | Amitril | Amitril ds | Amitrip | Amitryn | Amypres | Amzil | Cotrip | Depkey | Diprol | Eliwel | Emeltrip | Goldep | Ketrip | Latilin | Mitryp | Neurotrip | Normaline | Odep | Pryl-sr | Psycomer | Relidep | Sarotena | Tadamit | Trilin | Trip | Triplent | Tripoxy | Triptaz | Triptova | Tripty | Tryl | Tryptomer | Typlin | Vivax</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Deprezol</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin abcur</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Triptizol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Amiram | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amiplin | Amiprin | Lantron | Miketorin | Neuptanol | Schuvel | Tryptanol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Amiline | Amitrip | Amitriptyline | Tryptil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin | Amitriptyline | Enafon | Etravil | Myungin amitriptyline hcl | Sarotard | Tridanol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tryptizol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tryptizol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin | Amyzol | Apo amitriptylin | Elivel | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amineurin | Equilibrin | Redomex | Tryptizol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin | Amitriptylin neuraxpharm | Amyzol | Elivel | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anapsique | Tryptanol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amitrip | Amitriptyline | Endep | Tryptanol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Amyvil | Meditriline | Santryline | Timetriptylin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline HCL | Amitriptyline Hcl CF | Amitriptyline hcl mylan | Amitriptyline Hcl PCH | Amitriptyline hcl sandoz | Amitriptyline hcl strides | Amitriptylinehydrochloride | Sarotex | Tryptizol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin abcur | Amitriptylin orifarm | Amitriptylin sandoz | Amitriptyline | Saroten | Sarotex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amirol | Amitrip | Amitriptyline | Arrow Amitriptyline | Endep</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina | Anapsique | Tryptanol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Tripgen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amitin | Amitiptyline | Amitriptyline | Amotrip | Mitrin | Tryptanol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylinum | Amitriptylinum VP | Saroten</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline HCL | Elavil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adt zimaia | Amitriptilina | Tryptizol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alkym | Amitriptilina dasanti | Neurotol | Neurotol forte | Tritil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amirol | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amitriptilina arena | Amitriptylin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amiptilin | Amitriptylin | Amitriptyline | Amitriptyline ferein | Amitriptyline grindex | Amitriptyline nycomed | Amyzol | Apo amitriptyline | Elivel | Saroten | Vero amitriptylin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amirol | Amitriptyline | Apo amitriptyline | Endep | Pms amitriptyline | Saroten | Tryptizol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin abcur | Amitriptylin orifarm | Amitriptyline strides | Tryptizol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Apo amitriptyline | Tripta | Tryptanol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amyzol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyllin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline | Amitriptyline HCL | Conmitrip | Laroxyl | Medepress | Saroten | Tripnatol | Tripsyline | Triptin | Tripzol | Tryptanol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Amytril | Apo amitriptyline | Elavil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Triptilin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amilin | Amiplin | Amitriptyline | Modup | Pinsaun | Saroten | Tripyline | Tryptanol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Amitriptylin | Amitriptyllin Apo | Amysol | Elivel | Saroten | Saroten retard</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Amileb | Amiline | Amitivian | Amitriptyline</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amipharm | Amitie</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tryptanol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amilavil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Amderip | Amitriptylene | Amitriptyline Apex | Amitriptyline Austell | Gulf amitriptyline | Noriline | Saroten | Trepiline | Tryptanol | Veikirin | Zytrip</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Amitriptyline</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Amirol | Apo amitriptyline</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8968471">
<a name="8968471"></a>Alderman CP, Lee PC. Comment: Serotonin syndrome associated with combined sertraline-amitriptyline treatment. <i>Ann Pharmacother</i>. 1996;30(12):1499-1500. doi:10.1177/106002809603001227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8968471/pubmed" id="8968471" target="_blank">8968471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society. <i>Principles of analgesic use in the treatment of acute pain and cancer pain</i>. 6th ed. Glenview, IL: American Pain Society; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published May 2010. Accessed March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124882">
<a name="20124882"></a>American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine (ASA/ASRA). Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. <i>Anesthesiology</i>. 2010;112(4):810-833. doi:10.1097/ALN.0b013e3181c43103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20124882/pubmed" id="20124882" target="_blank">20124882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amitriptyline.2020.04">
<a name="Amitriptyline.2020.04"></a>Amitriptyline Hydrochloride [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amitriptyline.2017.08">
<a name="Amitriptyline.2017.08"></a>Amitriptyline Hydrochloride [prescribing information]. East Brunswick, NJ: Unichem Pharmaceuticals (USA); September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9374568">
<a name="9374568"></a>Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA. Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine. <i>Pediatrics</i>. 1997;100(6):977-981. doi:10.1542/peds.100.6.977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9374568/pubmed" id="9374568" target="_blank">9374568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21914052">
<a name="21914052"></a>Andersen PM, Abrahams S, Borasio GD, et al; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. <i>Eur J Neurol</i>. 2012;19(3):360-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21914052/pubmed" id="21914052" target="_blank">21914052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20402746">
<a name="20402746"></a>Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <i>Eur J Neurol</i>. 2010;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20402746/pubmed" id="20402746" target="_blank">20402746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25052053">
<a name="25052053"></a>Azadeh N, Kelemen K, Fonseca R. Amitriptyline-induced agranulocytosis with bone marrow confirmation. <i>Clin Lymphoma Myeloma Leuk</i>. 2014;14(5):e183-e185. doi:10.1016/j.clml.2014.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25052053/pubmed" id="25052053" target="_blank">25052053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7386673">
<a name="7386673"></a>Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. <i>Am J Psychiatry</i>. 1980;137(7):855-856. doi:10.1176/ajp.137.7.855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/7386673/pubmed" id="7386673" target="_blank">7386673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-Induced Serotonin Syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34454716">
<a name="34454716"></a>Bateman L, Bested AC, Bonilla HF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. <i>Mayo Clin Proc</i>. 2021;96(11):2861-2878. doi:10.1016/j.mayocp.2021.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/34454716/pubmed" id="34454716" target="_blank">34454716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20482606">
<a name="20482606"></a>Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J; EFNS. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. <i>Eur J Neurol</i>. 2010;17(11):1318-1325. doi: 10.1111/j.1468-1331.2010.03070.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20482606/pubmed" id="20482606" target="_blank">20482606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8795600">
<a name="8795600"></a>Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. <i>J Neurol Neurosurg Psychiatry</i>. 1996;61(3):285-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8795600/pubmed" id="8795600" target="_blank">8795600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biringer.2009">
<a name="Biringer.2009"></a>Biringer E, Rongve A, Rongve A. A review of modern antidepressants’ effects on neurocognitive function. <i>Current Psychiatry Reviews</i>. 2009;5. doi: 10.2174/157340009788971137.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18049300">
<a name="18049300"></a>Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(11):1503-1526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18049300/pubmed" id="18049300" target="_blank">18049300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9585655">
<a name="9585655"></a>Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. <i>J Am Acad Child Adolesc Psychiatry</i>. 1998;37(5):527-535. doi:10.1097/00004583-199805000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9585655/pubmed" id="9585655" target="_blank">9585655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4022081">
<a name="4022081"></a>Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. <i>N Engl J Med</i>. 1985;313(8):474-479. doi:10.1056/NEJM198508223130804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/4022081/pubmed" id="4022081" target="_blank">4022081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome [published correction appears in <i>N Engl J Med</i>. 2007;356(23):2437] [published correction appears in <i>N Engl J Med</i>. 2009;361(17):1714]. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22991449">
<a name="22991449"></a>Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. <i>Diabetes Care</i>. 2012;35(12):2451-2458. doi: 10.2337/dc12-0656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22991449/pubmed" id="22991449" target="_blank">22991449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21767283">
<a name="21767283"></a>Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. <i>Aliment Pharmacol Ther</i>. 2011;34(6):638-648. doi: 10.1111/j.1365-2036.2011.04775.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21767283/pubmed" id="21767283" target="_blank">21767283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7726331">
<a name="7726331"></a>Breyer-Pfaff U, Nill K, Entenmann KN, Gaertner HJ. Secretion of amitriptyline and metabolites into breast milk. <i>Am J Psychiatry.</i> 1995;152(5):812-813. doi:10.1176/ajp.152.5.812b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/7726331/pubmed" id="7726331" target="_blank">7726331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17100146">
<a name="17100146"></a>Briec F, Delaire C, Bouhour JB, Trochu JN. Recurrence of dilated cardiomyopathy after re-introduction of a tricyclic antidepressant. <i>Arch Mal Coeur Vaiss</i>. 2006;99(10):933-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17100146/pubmed" id="17100146" target="_blank">17100146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29937420">
<a name="29937420"></a>Briggs R, Carey D, McNicholas T, et al. The association between antidepressant use and orthostatic hypotension in older people: a matched cohort study. <i>J Am Soc Hypertens</i>. 2018;12(8):597-604.e1. doi:10.1016/j.jash.2018.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29937420/pubmed" id="29937420" target="_blank">29937420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482920">
<a name="21482920"></a>Bril V, England J, Franklin GM, et al. Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. <i>Neurology.</i> 2011;76(20):1758-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21482920/pubmed" id="21482920" target="_blank">21482920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6805016">
<a name="6805016"></a>Brixen-Rasmussen L, Halgrener J, Jørgensen A. Amitriptyline and nortriptyline excretion in human breast milk.<i> Psychopharmacology (Berl)</i>. 1982;76(1):94-95. doi:10.1007/BF00430765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6805016/pubmed" id="6805016" target="_blank">6805016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8736630">
<a name="8736630"></a>Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. <i>Drugs Aging</i>. 1996;8(6):459-476. doi:10.2165/00002512-199608060-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8736630/pubmed" id="8736630" target="_blank">8736630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15567552">
<a name="15567552"></a>Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. <i>Clin Neurol Neurosurg</i>. 2004;107(1):44-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15567552/pubmed" id="15567552" target="_blank">15567552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129762">
<a name="8129762"></a>Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. <i>Arthritis Rheum</i>. 1994;37(1):32-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8129762/pubmed" id="8129762" target="_blank">8129762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carruthers.2003">
<a name="Carruthers.2003"></a>Carruthers BM, Jain AK, DeMeirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. <i>Journal of Chronic Fatigue Syndrome</i>. 2003;11(1):7-115.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738724">
<a name="35738724"></a>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/35738724/pubmed" id="35738724" target="_blank">35738724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18510583">
<a name="18510583"></a>Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. <i>J Am Geriatr Soc</i>. 2008;56(7):1333-1341. doi:10.1111/j.1532-5415.2008.01737.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18510583/pubmed" id="18510583" target="_blank">18510583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3931149">
<a name="3931149"></a>Christensen P, Thomsen HY, Pedersen OL, et al. Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients. <i>Psychopharmacology (Berl)</i>. 1985;87(2):212-215. doi:10.1007/BF00431810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3931149/pubmed" id="3931149" target="_blank">3931149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clemens.2021">
<a name="Clemens.2021"></a>Clemens JQ. Interstitial cystitis/bladder pain syndrome: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3337866">
<a name="3337866"></a>Corrigan FM, Coulter F. Neuroleptic malignant syndrome, amitriptyline, and thioridazine. <i>Biol Psychiatry</i>. 1988;23(3):320-321. doi:10.1016/0006-3223(88)90044-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3337866/pubmed" id="3337866" target="_blank">3337866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898244">
<a name="24898244"></a>Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. <i>Aliment Pharmacol Ther</i>. 2014;40(3):309-317. doi:10.1111/apt.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/24898244/pubmed" id="24898244" target="_blank">24898244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8471189">
<a name="8471189"></a>Davison P, Wardrope J. Acute amitriptyline withdrawal and hyponatraemia. A case report. <i>Drug Saf</i>. 1993;8(1):78-80. doi:10.2165/00002018-199308010-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8471189/pubmed" id="8471189" target="_blank">8471189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi: 10.1016/j.psym.2014.01.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25135034">
<a name="25135034"></a>Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. <i>Pain Ther</i>. 2013;2(1):21-36. doi:10.1007/s40122-013-0006-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25135034/pubmed" id="25135034" target="_blank">25135034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6324897">
<a name="6324897"></a>Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. <i>Biol Psychiatry</i>. 1984;19(2):237-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6324897/pubmed" id="6324897" target="_blank">6324897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19393844">
<a name="19393844"></a>Dodick DW, Freitag F, Banks J, et al; CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. <i>Clin Ther</i>. 2009;31(3):542-559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19393844/pubmed" id="19393844" target="_blank">19393844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243617">
<a name="12243617"></a>Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. <i>Ann Pharmacother</i>. 2002;36(10):1647-1648. doi:10.1345/aph.1C091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/12243617/pubmed" id="12243617" target="_blank">12243617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8740607">
<a name="8740607"></a>Eija K, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. <i>Pain</i>. 1996;64(2):293-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8740607/pubmed" id="8740607" target="_blank">8740607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elavil.2018.08">
<a name="Elavil.2018.08"></a>Elavil (amitriptyline) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507636">
<a name="36507636"></a>ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S203-S215. doi:10.2337/dc23-S012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/36507636/pubmed" id="36507636" target="_blank">36507636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19708964">
<a name="19708964"></a>Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. <i>Eur J Neurol</i>. 2009;16(9):968-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19708964/pubmed" id="19708964" target="_blank">19708964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25857865">
<a name="25857865"></a>Eyler RF, Unruh ML, Quinn DK, Vilay AM. Psychotherapeutic agents in end-stage renal disease. <i>Semin</i>
<i>Dial</i>. 2015;28(4):417-426. doi:10.1111/sdi.12370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25857865/pubmed" id="25857865" target="_blank">25857865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.1">
<a name="Feldman.1"></a>Feldman EL. Management of diabetic neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575710">
<a name="25575710"></a>Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurol</i>. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25575710/pubmed" id="25575710" target="_blank">25575710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fitzcharles.2012">
<a name="Fitzcharles.2012"></a>Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome. http://fmguidelines.ca/. Published 2012. Accessed January 12, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19736267">
<a name="19736267"></a>Fortinguerra F, Clavenna A, and Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. <i>Pediatrics.</i> 2009;124(4):547-556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19736267/pubmed" id="19736267" target="_blank">19736267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20303115">
<a name="20303115"></a>Foster HE Jr, Hanno PM, Nickel JC, et al; Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. <i>J Urol</i>. 2010;183(5):1853-1858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20303115/pubmed" id="20303115" target="_blank">20303115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36791365">
<a name="36791365"></a>Frazier R, Li BUK, Venkatesan T. Diagnosis and management of cyclic vomiting syndrome: a critical review. <i>Am J Gastroenterol</i>. 2023;118(7):1157-1167. doi:10.14309/ajg.0000000000002216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/36791365/pubmed" id="36791365" target="_blank">36791365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17933616">
<a name="17933616"></a>Freidrichsdorf SJ, Kang TI. The management of pain in children with life-limiting illnesses. <i>Pediatr Clin N Amer</i>. 2007;54(5):645-672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17933616/pubmed" id="17933616" target="_blank">17933616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29946546">
<a name="29946546"></a>Gagnon J, Lussier MT, MacGibbon B, Daskalopoulou SS, Bartlett G. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. <i>Front Nutr</i>. 2018;5:47. doi:10.3389/fnut.2018.00047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29946546/pubmed" id="29946546" target="_blank">29946546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garza.1">
<a name="Garza.1"></a>Garza I. Central neuropathic facial pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7446764">
<a name="7446764"></a>Gawin FH, Markoff RA. Panic anxiety after abrupt discontinuation of amitriptyline. <i>Am J Psychiatry</i>. 1981;138(1):117-118. doi:10.1176/ajp.138.1.117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/7446764/pubmed" id="7446764" target="_blank">7446764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8444830">
<a name="8444830"></a>Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. <i>J Clin Psychiatry</i>. 1993;(suppl 54):16-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8444830/pubmed" id="8444830" target="_blank">8444830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gluckman.2019">
<a name="Gluckman.2019"></a>Gluckman SJ. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2020">
<a name="Goldenberg.2020"></a>Goldenberg DL. Initial treatment of fibromyalgia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509460">
<a name="15509460"></a>Graff-Radford SB. Myofascial pain: diagnosis and management. <i>Curr Pain Headache Rep</i>. 2004;8(6):463-467. doi:10.1007/s11916-004-0068-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15509460/pubmed" id="15509460" target="_blank">15509460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11014390">
<a name="11014390"></a>Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. <i>Clin J Pain</i>. 2000;16(3):188-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/11014390/pubmed" id="11014390" target="_blank">11014390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi: 10.1080/15622975.2017.1384850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10383563">
<a name="10383563"></a>Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. <i>Br J Clin Pharmacol</i>. 1999;48(1):71-78. doi:10.1046/j.1365-2125.1999.00973.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10383563/pubmed" id="10383563" target="_blank">10383563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hanno.2014">
<a name="Hanno.2014"></a>Hanno PM, Burks DA, Clemens JQ, et al. American Urological Association (AUA) guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. https://www.auanet.org/guidelines/interstitial-cystitis-(ic/bps)-guideline. Published 2011. Updated 2014. Accessed April 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hanno.2022">
<a name="Hanno.2022"></a>Hanno PM, Burks DA, Clemens Q, et al; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. https://www.auanet.org/guidelines-and-quality/guidelines/diagnosis-and-treatment-interstitial-of-cystitis/bladder-pain-syndrome-(2022). Published 2011. Updated 2022. Accessed August 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: How long is long enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19141768">
<a name="19141768"></a>Hauser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. <i>JAMA</i>. 2009;301(2):198-209. doi: 10.1001/jama.2008.944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19141768/pubmed" id="19141768" target="_blank">19141768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452526">
<a name="22452526"></a>Hauser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. <i>CNS Drugs</i>. 2012;26(4):297-307. doi: 10.2165/11598970-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22452526/pubmed" id="22452526" target="_blank">22452526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905532">
<a name="25905532"></a>Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. <i>J Oral Facial Pain Headache</i>. 2015;29(2):144-151. doi:10.11607/ofph.1408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25905532/pubmed" id="25905532" target="_blank">25905532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30129937">
<a name="30129937"></a>Haviv Y, Zini A, Sharav Y, Almoznino G, Benoliel R. Nortriptyline compared to amitriptyline for the treatment of persistent masticatory myofascial pain. <i>J Oral Facial Pain Headache</i>. 2019;33(1):7-13. doi:10.11607/ofph.1886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30129937/pubmed" id="30129937" target="_blank">30129937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911132">
<a name="25911132"></a>Hayasaka Y, Purgato M, Magni LR, et al. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. <i>J Affect Disord</i>. 2015;180:179-184. doi:10.1016/j.jad.2015.03.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25911132/pubmed" id="25911132" target="_blank">25911132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027010">
<a name="20027010"></a>Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. <i>J Clin Gastroenterol</i>. 2010;44(1):18-21. doi:10.1097/MCG.0b013e3181ac6489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20027010/pubmed" id="20027010" target="_blank">20027010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10940092">
<a name="10940092"></a>Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. <i>Headache.</i> 2000;40(7):539-549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10940092/pubmed" id="10940092" target="_blank">10940092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23594025">
<a name="23594025"></a>Hershey AD, Powers SW, Coffey CS, et al. Childhood and adolescent migraine prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. <i>Headache</i>. 2013;53(5):799-816. doi:10.1111/head.12105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23594025/pubmed" id="23594025" target="_blank">23594025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019a">
<a name="Hirsch.2019a"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 28, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019c">
<a name="Hirsch.2019c"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018">
<a name="Hirsch.2018"></a>Hirsch M, Birnbaum RJ. Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3995455">
<a name="3995455"></a>Hrdina PD, Lapierre YD, Koranyi EK. Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis. <i>Can J Psychiatry</i>. 1985;30(2):111-113. doi:10.1177/070674378503000205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3995455/pubmed" id="3995455" target="_blank">3995455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isaac.1">
<a name="Isaac.1"></a>Isaac Z. Management of non-radicular neck pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29552421">
<a name="29552421"></a>Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: A systematic review. <i>Innov Clin Neurosci</i>. 2017;14(7-8):24-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29552421/pubmed" id="29552421" target="_blank">29552421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22953086">
<a name="22953086"></a>Janati AB, Alghasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. <i>Case Rep Neurol Med</i>. 2012;2012:183252. doi:10.1155/2012/183252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22953086/pubmed" id="22953086" target="_blank">22953086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23406477">
<a name="23406477"></a>Kalita J, Bhoi Sk, Misra UK. Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. <i>Acta Neurol Scand</i>. 2013;128(1):65-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23406477/pubmed" id="23406477" target="_blank">23406477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6736501">
<a name="6736501"></a>Kashani JH, Shekim WO, and Reid JC, “Amitriptyline in Children With Major Depressive Disorder: A Double-Blind Crossover Pilot Study,” <i>J Am Acad Child Psychiatry</i>, 1984, 23(3):348-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6736501/pubmed" id="6736501" target="_blank">6736501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21355098">
<a name="21355098"></a>Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. <i>Diabetes Care</i>. 2011;34(4):818-822. doi: 10.2337/dc10-1793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21355098/pubmed" id="21355098" target="_blank">21355098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18620801">
<a name="18620801"></a>Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. <i>Clin Neurol Neurosurg</i>. 2008;110(10):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18620801/pubmed" id="18620801" target="_blank">18620801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7031113">
<a name="7031113"></a>Kramer AD, Feiguine RJ. Clinical effects of amitriptyline in adolescent depression. A pilot study. <i>J Am Acad Child Psychiatry</i>. 1981;20(3):636-644. doi:10.1016/s0002-7138(09)61650-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/7031113/pubmed" id="7031113" target="_blank">7031113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:doi: 10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738725">
<a name="35738725"></a>Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. <i>Gastroenterology</i>. 2022;163(1):137-151. doi:10.1053/j.gastro.2022.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/35738725/pubmed" id="35738725" target="_blank">35738725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S; American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2004;63(12):2215-2224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15012660">
<a name="15012660"></a>Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. <i>Headache</i>. 2004;44(3):230-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15012660 /pubmed" id="15012660 " target="_blank">15012660 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18188866">
<a name="18188866"></a>Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. doi:10.1002/pds.1546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18188866/pubmed" id="18188866" target="_blank">18188866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Li.1">
<a name="Li.1"></a>Li BUK. Cyclic vomiting syndrome. Post TW, ed. UpToDate, ed. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393. doi:10.1097/MPG.0b013e318173ed39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3971655">
<a name="3971655"></a>Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. <i>Clin Pharmacol Ther</i>. 1985;37(3):301-307. doi:10.1038/clpt.1985.44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3971655/pubmed" id="3971655" target="_blank">3971655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923523">
<a name="28923523"></a>Lien YH. Antidepressants and Hyponatremia. <i>Am J Med</i>. 2018;131(1):7-8. doi:10.1016/j.amjmed.2017.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/28923523/pubmed" id="28923523" target="_blank">28923523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.2018">
<a name="Longstreth.2018"></a>Longstreth GF, Lacy BE. Functional dyspepsia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5923732">
<a name="5923732"></a>Lowe RF. Amitriptyline and glaucoma. <i>Med J Aust</i>. 1966;2(11):509-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/5923732/pubmed" id="5923732" target="_blank">5923732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27377815">
<a name="27377815"></a>Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. <i>Ann Rheum Dis</i>. 2017;76(2):318-328. doi: 10.1136/annrheumdis-2016-209724.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27377815/pubmed" id="27377815" target="_blank">27377815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly.<i> Can J Psychiatry.</i> 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826316">
<a name="9826316"></a>Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. <i>Circulation</i>. 1998;98(21):2290-2295. doi:10.1161/01.cir.98.21.2290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9826316/pubmed" id="9826316" target="_blank">9826316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1560801">
<a name="1560801"></a>Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. <i>N Engl J Med</i>. 1992;326(19):1250-1256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/1560801/pubmed" id="1560801" target="_blank">1560801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3412591">
<a name="3412591"></a>Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. <i>Neurology</i>. 1988;38(9):1427-1432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3412591/pubmed" id="3412591" target="_blank">3412591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1519713">
<a name="1519713"></a>McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. <i>Anaesthesia</i>. 1992;47(8):646-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/1519713/pubmed" id="1519713" target="_blank">1519713</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehta.1">
<a name="Mehta.1"></a>Mehta NR, Keith DK. Temporomandibular disorders in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miaskowski.2008">
<a name="Miaskowski.2008"></a>Miaskowski C, Bair M, Chou R, et al, eds. <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. Glenview, IL: American Pain Society; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21745832">
<a name="21745832"></a>Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. <i>Am J Hosp Palliat Care</i>. 2012;29(3):177-182. doi: 10.1177/1049909111412539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/21745832/pubmed" id="21745832" target="_blank">21745832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17372630">
<a name="17372630"></a>Moulin DE, Clark AJ, Gilron I, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. <i>Pain Res Manag</i>. 2007;12(1):13-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17372630/pubmed" id="17372630" target="_blank">17372630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24566587">
<a name="24566587"></a>Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). <i>Osteoporos Int</i>. 2014;25(5):1473-1481. doi:10.1007/s00198-014-2649-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/24566587/pubmed" id="24566587" target="_blank">24566587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397569">
<a name="30397569"></a>Mullen S. Major depressive disorder in children and adolescents. <i>Ment Health Clin</i>. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30397569/pubmed" id="30397569" target="_blank">30397569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The treatment and management of depression in adults (updated edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2017">
<a name="NICE.2017"></a>National Collaborating Centre for Nursing and Supportive Care. Clinical practice guideline: irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. National Institute for Health and Clinical Excellence. https://www.nice.org.uk/guidance/cg61/evidence/full-guidance-196701661. Published February 2008. Updated March 2017. Accessed July 17, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.3">
<a name="NICE.3"></a>National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management. NICE clinical guideline NG134. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng134. Published June 25, 2019. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9031998">
<a name="9031998"></a>Nisijima K, Shimizu M, Abe T, Ishiguro T. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. <i>Int Clin Psychopharmacol</i>. 1996;11(4):289-290. doi:10.1097/00004850-199612000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9031998/pubmed" id="9031998" target="_blank">9031998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi: 10.1177/0897190012467210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11126303">
<a name="11126303"></a>Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. <i>Am J Med</i>. 2000;108(2):106-111. doi:10.1016/s0002-9343(99)00425-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/11126303/pubmed" id="11126303" target="_blank">11126303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413171">
<a name="31413171"></a>Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society (AAN/AHS). <i>Neurology</i>. 2019;93(11):487-499. doi:10.1212/WNL.0000000000008095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/31413171/pubmed" id="31413171" target="_blank">31413171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15320756">
<a name="15320756"></a>Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. <i>Curr Pharm Des</i>. 2004;10(20):2463-2475. doi:10.2174/1381612043383872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15320756/pubmed" id="15320756" target="_blank">15320756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10099756">
<a name="10099756"></a>Pagano R. Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. <i>Aust N Z J Obstet Gynaecol</i>. 1999;39(1):79-83. doi:10.1111/j.1479-828x.1999.tb03450.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10099756/pubmed" id="10099756" target="_blank">10099756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15156966">
<a name="15156966"></a>Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. <i>Am J Health Syst Pharm. </i>2004;61(9):899-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15156966/pubmed" id="15156966" target="_blank">15156966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10727586">
<a name="10727586"></a>Perry NK. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline. <i>Postgrad Med J</i>. 2000;76(894):254-256. doi:10.1136/pmj.76.894.254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/10727586/pubmed" id="10727586" target="_blank">10727586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9586488">
<a name="9586488"></a>Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. <i>Cranio</i>. 1997;15(1):53-56. doi:10.1080/08869634.1997.11745992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9586488/pubmed" id="9586488" target="_blank">9586488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6757842">
<a name="6757842"></a>Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. <i>Pain</i>. 1982;14(2):169-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6757842/pubmed" id="6757842" target="_blank">6757842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3805339">
<a name="3805339"></a>Pittard WB 3rd, O'Neal W Jr. Amitriptyline excretion in human milk. <i>J Clin Psychopharmacol.</i> 1986;6(6):383-384. doi:10.1097/00004714-198612000-00024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3805339/pubmed" id="3805339" target="_blank">3805339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11065017">
<a name="11065017"></a>Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. <i>J Oral Rehabil</i>. 2000;27(10):834-841. doi:10.1046/j.1365-2842.2000.00572.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/11065017/pubmed" id="11065017" target="_blank">11065017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999003">
<a name="27999003"></a>Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2017;40(1):136-154. doi: 10.2337/dc16-2042.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27999003/pubmed" id="27999003" target="_blank">27999003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27788026">
<a name="27788026"></a>Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. <i>N Engl J Med</i>. 2017;376(2):115-124. doi:10.1056/NEJMoa1610384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27788026/pubmed" id="27788026" target="_blank">27788026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24368463">
<a name="24368463"></a>Powers SW, Kashikar-Zuck SM, Allen JR, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. <i>JAMA</i>. 2013;310(24):2622-2630. doi:10.1001/jama.2013.282533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/24368463/pubmed" id="24368463" target="_blank">24368463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16939528">
<a name="16939528"></a>Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. <i>Br J Clin Pharmacol</i>. 2007;63(1):128-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16939528/pubmed" id="16939528" target="_blank">16939528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2140373">
<a name="2140373"></a>Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. <i>J Clin Psychopharmacol</i>. 1990;10(2):88-95. doi:10.1097/00004714-199004000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/2140373/pubmed" id="2140373" target="_blank">2140373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4008451">
<a name="4008451"></a>Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. <i>J Clin Psychiatry</i>. 1985;46(7):276-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/4008451/pubmed" id="4008451" target="_blank">4008451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34965987">
<a name="34965987"></a>Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. <i>Neurology</i>. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/34965987/pubmed" id="34965987" target="_blank">34965987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci.</i> 2012;39(2 suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137. doi:10.1007/s00198-012-2015-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9715427">
<a name="9715427"></a>Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. <i>J Gastroenterol Hepatol</i>. 1998;13(7):738-741.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9715427/pubmed" id="9715427" target="_blank">9715427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224097">
<a name="33224097"></a>Raucci U, Borrelli O, Di Nardo G, et al. Cyclic vomiting syndrome in children. <i>Front Neurol</i>. 2020;11:583425. doi:10.3389/fneur.2020.583425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/33224097/pubmed" id="33224097" target="_blank">33224097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20443647">
<a name="20443647"></a>Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. <i>CNS Drugs</i>. 2010;24(6):501-526. doi:10.2165/11533180-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/20443647/pubmed" id="20443647" target="_blank">20443647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riedel.1995">
<a name="Riedel.1995"></a>Riedel WJ, van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. <i>CNS Drugs.</i> 1995;3(4):245-259.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32894454">
<a name="32894454"></a>Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. <i>Drugs Aging</i>. 2020;37(10):725-738. doi:10.1007/s40266-020-00796-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/32894454/pubmed" id="32894454" target="_blank">32894454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12889679">
<a name="12889679"></a>Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, Ambrosano GM, de Barbosa JR. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. <i>Cranio</i>. 2003;21(3):221-225. doi:10.1080/08869634.2003.11746254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/12889679/pubmed" id="12889679" target="_blank">12889679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roos.1983">
<a name="Roos.1983"></a>Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. <i>Br J Clin Pharmac</i>. 1983;15:439S-445S.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16275598">
<a name="16275598"></a>Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. <i>J Pain</i>. 2005;6(11):741-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16275598/pubmed" id="16275598" target="_blank">16275598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1592445">
<a name="1592445"></a>Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. <i>Hypertension</i>. 1992;19(6 Pt 1):508-519. doi:10.1161/01.hyp.19.6.508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/1592445/pubmed" id="1592445" target="_blank">1592445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25735839">
<a name="25735839"></a>Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis [published correction appears in <i>Br J Clin Pharmacol</i>. 2015 Oct;80(4):921-6]. <i>Br J Clin Pharmacol</i>. 2015;80(2):209-220. doi:10.1111/bcp.12617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25735839/pubmed" id="25735839" target="_blank">25735839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28709467">
<a name="28709467"></a>Sabah KM, Chowdhury AW, Islam MS, Saha BP, Kabir SR, Kawser S. Amitriptyline-induced ventricular tachycardia: a case report. <i>BMC Res Notes</i>. 2017;10(1):286. doi:10.1186/s13104-017-2615-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/28709467/pubmed" id="28709467" target="_blank">28709467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6723762">
<a name="6723762"></a>Sandoz M, Vandel S, Vandel B, et al. Metabolism of amitriptyline in patients with chronic renal failure. <i>Eur J Clin Pharmacol</i>. 1984;26(2):227-232. doi:10.1007/BF00630290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6723762/pubmed" id="6723762" target="_blank">6723762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16416358">
<a name="16416358"></a>Sator-Katzenschlager SM, Scharbert G, Kress HG, et al. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. <i>Wien Klin Wochenschr</i>. 2005;117(21-22):761-768. doi:10.1007/s00508-005-0464-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16416358/pubmed" id="16416358" target="_blank">16416358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3536890">
<a name="3536890"></a>Scharf MB, Hirschowitz J, Zemlan FP, Lichstein M, Woods M. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. <i>J Clin Psychiatry</i>. 1986;47(12):587-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/3536890/pubmed" id="3536890" target="_blank">3536890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6825390">
<a name="6825390"></a>Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. <i>Clin Pharmacokinet</i>. 1985;10(3):257-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6825390/pubmed" id="6825390" target="_blank">6825390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2022">
<a name="Schwedt.2022"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton, RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in <i>Neurology. </i>2013;80(9):871].<i> Neurology.</i> 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27113954">
<a name="27113954"></a>Sinha S, Simlai J, Praharaj SK. Very low dose amitriptyline for clozapine-associated sialorrhea. <i>Curr Drug Saf</i>. 2016;11(3):262-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27113954/pubmed" id="27113954" target="_blank">27113954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22487791">
<a name="22487791"></a>Squires N, Wills A, Rowson J. The management of drooling in adults with neurological conditions. <i>Curr Opin Otolaryngol Head Neck Surg</i>. 2012;20(3):171-176. doi: 10.1097/MOO.0b013e32835328ec.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22487791/pubmed" id="22487791" target="_blank">22487791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>, 2008;42(9):1290-1297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25921377">
<a name="25921377"></a>Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. <i>Gastroenterology</i>. 2015;149(2):340-349.e2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25921377/pubmed" id="25921377" target="_blank">25921377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16285971">
<a name="16285971"></a>Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. <i>Gastroenterology</i>. 2005;129(5):1756-1780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16285971/pubmed" id="16285971" target="_blank">16285971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8813100">
<a name="8813100"></a>Taniguchi S, Hamada T. Photosensitivity and thrombocytopenia due to amitriptyline. <i>Am J Hematol</i>. 1996;53(1):49-50. doi:10.1002/1096-8652(199609)53:1&lt;49::aid-ajh2830530102&gt;3.0.co;2-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8813100/pubmed" id="8813100" target="_blank">8813100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4049459">
<a name="4049459"></a>Tasset JJ, Singh S, Pesce AJ. Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. <i>Ther Drug Monit</i>. 1985;7(3):255-257. doi:10.1097/00007691-198507030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/4049459/pubmed" id="4049459" target="_blank">4049459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tauben.1">
<a name="Tauben.1"></a>Tauben D, Stacey BR. Pharmacologic management of chronic non-cancer pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taylor.2018">
<a name="Taylor.2018"></a>Taylor FR. Tension-type headache in adults: Preventive treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8452661">
<a name="8452661"></a>Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. <i>Drug Saf</i>. 1993;8(3):186-212. doi:10.2165/00002018-199308030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/8452661/pubmed" id="8452661" target="_blank">8452661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27870551">
<a name="27870551"></a>Uguz F. Poor feeding and severe sedation in a newborn nursed by a mother on a low dose of amitriptyline. <i>Breastfeed Med</i>. 2017;12:67-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/27870551/pubmed" id="27870551" target="_blank">27870551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADod.2016">
<a name="VADod.2016"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18248658">
<a name="18248658"></a>Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. <i>Aliment Pharmacol Ther</i>. 2008;27(8):678-684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18248658/pubmed" id="18248658" target="_blank">18248658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29202395">
<a name="29202395"></a>van Beekhuizen HJ, Oost J, van der Meijden WI. Generalized unprovoked vulvodynia; a retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2018;220:118-121. doi:10.1016/j.ejogrb.2017.10.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29202395/pubmed" id="29202395" target="_blank">29202395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11250852">
<a name="11250852"></a>van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. <i>BMJ</i>. 2001;322(7287):654-657. doi:10.1136/bmj.322.7287.654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/11250852/pubmed" id="11250852" target="_blank">11250852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23265229">
<a name="23265229"></a>van Hateren KJ, Kleefstra N, Blanker MH, et al. Orthostatic hypotension, diabetes, and falling in older patients: a cross-sectional study. <i>Br J Gen Pract</i>. 2012;62(603):e696-e702. doi:10.3399/bjgp12X656838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/23265229/pubmed" id="23265229" target="_blank">23265229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15247722">
<a name="15247722"></a>van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. <i>J Urol</i>. 2004;172(2):533-536. doi: 10.1097/01.ju.0000132388.54703.4d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/15247722/pubmed" id="15247722" target="_blank">15247722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31241819">
<a name="31241819"></a>Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society (ANMS) and the Cyclic Vomiting Syndrome Association (CVSA). <i>Neurogastroenterol Motil</i>. 2019;31(suppl 2):e13604. doi:10.1111/nmo.13604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/31241819/pubmed" id="31241819" target="_blank">31241819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9430812">
<a name="9430812"></a>Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. <i>Clin J Pain</i>. 1997;13(4):313-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9430812/pubmed" id="9430812" target="_blank">9430812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75‐81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.2018">
<a name="Wald.2018"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22936860">
<a name="22936860"></a>Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. <i>Drug Healthc Patient Saf</i>. 2012;4:93-101. doi:10.2147/DHPS.S28804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/22936860/pubmed" id="22936860" target="_blank">22936860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1738571">
<a name="1738571"></a>Watson CP, Chipman M, Reed K, Evans RJ, Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. <i>Pain</i>. 1992;48(1):29-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/1738571/pubmed" id="1738571" target="_blank">1738571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6283422">
<a name="6283422"></a>Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. <i>Neurology</i>. 1982;32(6):671-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/6283422/pubmed" id="6283422" target="_blank">6283422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9781549">
<a name="9781549"></a>Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. <i>Neurology</i>. 1998;51(4):1166-1171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9781549/pubmed" id="9781549" target="_blank">9781549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25224526">
<a name="25224526"></a>Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S; American Gastroenterological Association. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. <i>Gastroenterology</i>. 2014;147(5):1146-1148. doi:10.1053/j.gastro.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/25224526/pubmed" id="25224526" target="_blank">25224526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33276542">
<a name="33276542"></a>Windsor RB, Sierra M, Zappitelli M, McDaniel M. Beyond amitriptyline: a pediatric and adolescent oriented narrative review of the analgesic properties of psychotropic medications for the treatment of complex pain and headache disorders. <i>Children (Basel)</i>. 2020;7(12):268. doi:10.3390/children7120268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/33276542/pubmed" id="33276542" target="_blank">33276542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et a. The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol.</i> 2009;114(3):703-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9186793">
<a name="9186793"></a>Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. <i>J Affect Disord</i>. 1997;43(3):225-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/9186793/pubmed" id="9186793" target="_blank">9186793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.2020">
<a name="Zeltzer.2020"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-860894">
<a name="860894"></a>Ziegler VE, Clayton PJ, Biggs JT. A comparison study of amitriptyline and nortriptyline with plasma levels. <i>Arch Gen Psychiatry</i>. 1977;34(5):607-612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/860894/pubmed" id="860894" target="_blank">860894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2234996">
<a name="2234996"></a>Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. <i>Pain</i>. 1990;42(1):35-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amitriptyline-pediatric-drug-information/abstract-text/2234996/pubmed" id="2234996" target="_blank">2234996</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12598 Version 653.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
